Venus Remedies
Venus Remedies Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Venus Remedies Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Venus Remedies Ltd trades at a P/E of 23.41× and P/B of 4.05×.
Valuation
Profitability
Growth
Financial Health
Venus Remedies Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Venus Remedies Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Venus Remedies Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Venus Remedies Ltd, switchable between annual and quarterly views, consolidated or standalone.
Venus Remedies Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,330.8 Cr and reported EPS of ₹76.93.
| Period | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 372 | 341 | 548 | 599 | 556 | 601 | 648 | 770 |
| Other Income | 2 | 5 | 20 | 8 | 10 | 12 | 21 | 13 |
| Total Income | 375 | 347 | 568 | 607 | 566 | 613 | 669 | 782 |
| Cost of Goods Sold (COGS) | 205 | 174 | 341 | 385 | 331 | 355 | 379 | 387 |
| Gross Profit | 167 | 167 | 207 | 213 | 225 | 247 | 269 | 382 |
| +Operating Expenses | 128 | 126 | 154 | 151 | 164 | 187 | 206 | 235 |
| EBITDA | 39 | 41 | 54 | 62 | 60 | 60 | 64 | 147 |
| +Non-Operating Expenses | 69 | 37 | 72 | 34 | 33 | 27 | 32 | 26 |
| Profit Before Tax (PBT) | -28 | -8 | 49 | 36 | 38 | 45 | 72 | 134 |
| +Tax Expense | 3 | 2 | -13 | -4 | 11 | 16 | 24 | 31 |
| Profit After Tax (PAT) | -31 | -10 | 62 | 41 | 27 | 28 | 45 | 103 |
| Earnings Per Share (EPS) | -24.87 | -8.10 | 50.04 | 30.47 | 19.88 | 21.32 | 33.90 | 76.89 |
| Diluted Shares Outstanding (Nos.) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| +Additional Disclosures | 608 | 520 | 883 | 955 | 852 | 922 | 985 | 1,035 |
| Sales Growth % | — | -8.31 | 60.52 | 9.22 | -7.21 | 8.27 | 7.72 | 18.79 |
| YoY Sales Growth % | — | — | 60.52 | 9.22 | -7.21 | 8.27 | 7.72 | 18.79 |
| Material Cost % | 55 | 49 | 63 | 64 | 57 | 57 | 54 | 50 |
| Employee Cost % | 11 | 13 | 8 | 9 | 11 | 12 | 12 | 12 |
| Other Cost % | 24 | 24 | 20 | 16 | 19 | 19 | 19 | 19 |
| OPM % | 11 | 12 | 10 | 10 | 11 | 10 | 10 | 19 |
| Tax % | -11 | -24 | -27 | -12 | 30 | 36 | 33 | 23 |
| Profit Growth % | — | — | 717.77 | -34.07 | -34.76 | 7.25 | 59.04 | 126.79 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 6 | 9 | 19 | 29 | 28 | 33 | 41 | 122 |
Venus Remedies segment analysis: revenue and profit mix.
Disclosed business segments at Venus Remedies with their share of revenue and profit, switchable between consolidated and standalone reporting.
Venus Remedies discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Venus Remedies Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Venus Remedies Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Venus Remedies Ltd's investment case rests on 10 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Zero debt-to-equity ratio indicates strong financial stability and low leverage.
Exceptional quarterly profit growth of 687.00% reflects strong operational performance.
Robust quarterly sales growth of 21.40% indicates increasing demand and market penetration.
Attractive P/E ratio of 11.01 suggests potential undervaluation compared to peers.
Diversified product portfolio across critical care and herbal medicine segments.
What can break it.
Relatively low ROE (4.64%) and ROCE (11.10%) indicate scope for efficiency.
Absence of dividend yield (0.00%) may deter income-focused investors.
Stagnant 5-year EPS growth of 0.00% indicates lack of long-term earnings expansion.
Negative 5-year Free Operating Cash Flow CAGR of -0.42% is concerning.
Current stock price significantly below 52-week high suggests recent downtrend.
What would change my mind.
Trim if P/E re-rates above 30. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 2.37. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 12%. The operating engine is no longer compounding capital efficiently.
Venus Remedies Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Venus Remedies Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Venus Remedies Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Venus Remedies Ltd — derived from the live tape, not yesterday's close.
Venus Remedies Ltd last traded at ₹1,797.5 with an intraday range of ₹1,706.8–₹1,800.8 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1797.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2017.93 | +220.43 | +12.26% |
| R3 | 1923.93 | +126.43 | +7.03% |
| R2 | 1862.37 | +64.87 | +3.61% |
| R1 | 1829.93 | +32.43 | +1.80% |
| PIVOT | 1768.37 | -29.13 | -1.62% |
| CURRENT | 1797.50 | — | — |
| S1 | 1547.93 | -249.57 | -13.88% |
| S2 | 1641.93 | -155.57 | -8.65% |
| S3 | 1674.37 | -123.13 | -6.85% |
| S4 | 1735.93 | -61.57 | -3.43% |
VENUSREM is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ~
Trading Above opening range, showing Bullishness
Venus Remedies Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Venus Remedies Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Venus Remedies Ltd stood at 44.1% of traded volume, against a 20-day average of 65.6%.
Venus Remedies announcements: results, concalls, ratings, M&A.
Filings Venus Remedies sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Venus Remedies files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 60 documents below.
Updates
Venus Remedies Limited has informed the Exchange regarding 'Venus Remedies Limited Secures Renewal of Prestigious DSIR in-house R&D Recognition'.
Copy of Newspaper Publication
Venus Remedies Limited has informed the Exchange about Copy of Newspaper Publication
Updates
Venus Remedies Limited has informed the Exchange regarding 'Venus Remedies receives Saudi FDA approval for Plerixafor its first Maketing…
Disclosure under SEBI Takeover Regulations
Venus Remedies Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Copy of Newspaper Publication
Venus Remedies Limited has informed the Exchange about copy of newspaper publication of notice to shareholders on transfer of Physical shares as per…
Venus Remedies dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Venus Remedies has declared, sequenced by announce and record date.
Venus Remedies corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Venus Remedies Ltd: business, sector, key facts.
What Venus Remedies Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Venus Remedies Ltd operates in the Healthcare, listed as NSE: VENUSREM, BSE: 526953.
Venus Remedies Limited is a pharmaceutical company headquartered in Panchkula, India, operating both domestically and internationally. Their core business revolves around the research, development, manufacturing, and distribution of a wide array of pharmaceutical products.
The company's product portfolio spans a diverse range of therapeutic areas, catering to a broad spectrum of medical needs. These therapeutic areas include, but are not limited to: analgesics (pain relievers), antipyretics (fever reducers), anti-diabetics, antibiotics, antiemetics (anti-nausea medications), antivirals, cardiovascular medications, disinfectants and antiseptics, gastrointestinal therapies, hepatoprotective agents (liver protectants), hormone therapies, immunostimulants, iron supplements, muscle relaxants, neurological medications, oncology medications, respiratory medications, and anticoagulants (blood thinners).
Beyond conventional pharmaceuticals, Venus Remedies also maintains a significant presence in the herbal medicine market, offering a portfolio of products derived from natural sources. This demonstrates a commitment to providing diverse treatment options and potentially catering to a broader consumer base interested in alternative or complementary therapies.
Established in 1989, Venus Remedies has a history of nearly three and a half decades in the pharmaceutical industry. This longevity suggests a degree of stability and market experience, although the specific details of their market share and financial performance would require further information beyond the provided text.
In summary, Venus Remedies' business model is built upon a diversified product portfolio encompassing both conventional and herbal pharmaceuticals, targeting a wide array of therapeutic areas and serving both domestic and international markets. Their long operational history suggests established processes and infrastructure within the pharmaceutical industry.
Questions investors ask about Venus Remedies Ltd (VENUSREM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Venus Remedies Ltd (VENUSREM)?
The current share price of Venus Remedies Ltd (VENUSREM) is ₹1,797.5. Today, the stock has gained by ₹82.40 (4.80%), trading in a range of ₹1,706.8 to ₹1,800.8. The stock opened at ₹1,749.9 with a trading volume of 2,46,228 shares.
02Is Venus Remedies Ltd stock a good investment for long-term?
Venus Remedies Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,330.8 crores, P/E ratio of 23.41, ROE of 16.79%, and ROCE of 11.10%. The dividend yield stands at 0.56%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Venus Remedies Ltd stock?
The 52-week high price of Venus Remedies Ltd (VENUSREM) is ₹1,943.8, while the 52-week low is ₹416. Currently trading at ₹1,797.5, the stock is 90.4% away from its 52-week low and 7.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Venus Remedies Ltd stock at the current price?
Whether to buy Venus Remedies Ltd stock at ₹1,797.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 23.41 and P/B ratio of 4.05. Today's performance shows a gain of 4.80%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Venus Remedies Ltd and when is the next dividend?
Venus Remedies Ltd offers a dividend yield of 0.56%, which means for every ₹100 invested at the current price of ₹1,797.5, you can expect to receive approximately ₹0.56 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Venus Remedies Ltd?
Venus Remedies Ltd's key financial metrics include: P/E Ratio: 23.41, P/B Ratio: 4.05, ROE: 16.79%, ROCE: 11.10%, Dividend Yield: 0.56%, EPS: ₹76.93, Book Value: ₹444.63, and Debt-to-Equity: 1.87. The company's market cap stands at ₹2,330.8 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Venus Remedies Ltd stock performing today in the market?
Venus Remedies Ltd stock opened at ₹1,749.9 and is currently trading at ₹1,797.5, showing a gain of ₹82.40 (4.80%). The intraday high is ₹1,800.8 and low is ₹1,706.8. The trading volume stands at 2,46,228 shares, indicating moderate market participation today.
08What is the P/E ratio of Venus Remedies Ltd and what does it indicate?
Venus Remedies Ltd has a Price-to-Earnings (P/E) ratio of 23.41, which means investors are willing to pay ₹23.41 for every ₹1 of earnings. With an EPS of ₹76.93, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Venus Remedies Ltd (VENUSREM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- All Technical ScreenersScreener
- All Trading StrategiesStrategy